ImmunOs Therapeutics Funding: $89M Raised, Series B (2022)
ImmunOs Therapeutics is based in Schlieren, Switzerland. It has raised $89M in total funding. Latest round: Series B.
ImmunOs Therapeutics funding overview
ImmunOs Therapeutics is based in Schlieren, Switzerland. ImmunOs Therapeutics has raised $89M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in January 2022. The round record for ImmunOs Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, BioMed Partners, Redalpine and 5 others. 11 distinct backers are named across the disclosed rounds.
Frequently asked about ImmunOs Therapeutics funding
How much has ImmunOs Therapeutics raised?
ImmunOs Therapeutics has raised $89M in total disclosed funding across the rounds on record.
Who has invested in ImmunOs Therapeutics?
Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, BioMed Partners, Redalpine are named among the investors backing ImmunOs Therapeutics.
What was the latest ImmunOs Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2022.
Where is ImmunOs Therapeutics based?
ImmunOs Therapeutics is based in Schlieren, Switzerland.
When did ImmunOs Therapeutics last raise?
The last disclosed ImmunOs Therapeutics round closed in January 2022 at Series B.
We update the ImmunOs Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Schlieren and their backers are listed below.
